^
Association details:
| Biomarker: | ASXL1 mutation |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
332 ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase
Published date:
11/03/2022
Excerpt:
222 CML patients from the ongoing German TIGER study (CML-V; NCT01657604) were investigated...patients carrying an ASXL1 mutation at diagnosis showed a less favorable molecular response to nilotinib treatment, as a major molecular response (MMR) was achieved less frequently at month 12 (55% vs. 85%; p=0.0036), month 18 (60% vs. 89%; p=0.0018), and month 24 (65% vs. 89%; p=0.0076) compared to patients without mutations.
DOI:
https://doi.org/10.1182/blood-2022-165041
Trial ID:
